Dosage Forms in Drug Delivery: State of the Art and Future Perspectives

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Pharmaceutical Technology, Manufacturing and Devices".

Deadline for manuscript submissions: closed (31 July 2025) | Viewed by 2343

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain
Interests: nanomedicine; cancer; controlled release systems; prosthetic infection; microparticles
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The design and optimization of dosage forms play a pivotal role in drug delivery. These dosage forms are very varied, including oral dosage forms (e.g., tablets or capsules), injectable dosage forms (e.g., microparticles, implants, nanoparticles, or liposomes), and topical dosage forms (e.g., patches). These formulations have a significant impact on absorption, distribution, and patient compliance. This Special Issue, entitled "Dosage Forms in Drug Delivery: State of the Art and Future Perspectives", aims to provide an in-depth examination of the latest advancements and emerging trends in dosage form design and their implications for drug delivery. It will cover a wide range of topics, including novel formulation approaches, biopharmaceutical considerations, and the use of advanced materials and technologies to enhance drug release, stability, and targeting. The purpose of this Special Issue is to present cutting-edge research and innovations in dosage form design and development, highlighting both current practices and future trends. By bringing together leading experts and emerging voices in the field, this Special Issue aims to foster advancements in formulation science and enhance the precision and effectiveness of drug delivery systems.

We look forward to receiving your contributions. 

Dr. Cristina Martín-Sabroso
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • dosage forms
  • drug delivery
  • tablets
  • capsules
  • nanoparticles
  • liposomes
  • patches
  • microparticles
  • implants
  • therapeutic efficacy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

19 pages, 4580 KB  
Article
Rapidly Dissolving Microneedles Incorporating Lidocaine Hydrochloride: A PVP/PVA-Based Approach for Local Anesthesia
by Su Young Jin, Eugene Jae-Jin Park, Sae Min Kwon, Hyoung-Seok Jung and Dong Wuk Kim
Pharmaceutics 2025, 17(9), 1100; https://doi.org/10.3390/pharmaceutics17091100 - 23 Aug 2025
Viewed by 215
Abstract
Background/Objectives: Lidocaine is a widely used local anesthetic, but injections and topical creams are often painful or slow in onset. This study aimed to develop dissolving microneedles incorporating lidocaine hydrochloride for rapid and convenient local anesthesia. Methods: Six formulations were prepared with polyvinylpyrrolidone [...] Read more.
Background/Objectives: Lidocaine is a widely used local anesthetic, but injections and topical creams are often painful or slow in onset. This study aimed to develop dissolving microneedles incorporating lidocaine hydrochloride for rapid and convenient local anesthesia. Methods: Six formulations were prepared with polyvinylpyrrolidone (PVP) and polyvinyl alcohol (PVA) and evaluated for mechanical strength, skin insertion, drug release, and transdermal permeability. Results: Sharp pyramidal microneedles were successfully fabricated, with PVP–PVA mixtures producing stronger needles than single polymers. The optimized F5 formulation showed high strength (>32 N), efficient skin insertion (four parafilm layers), and rapid release (>80% within 15 min). In ex vivo studies, F5 delivered >600 µg/mL lidocaine in 15 min, over three times the therapeutic level and much faster than Emla cream (5%). Conclusions: PVP–PVA microneedles represent a promising platform for painless, rapid local anesthesia, combining the benefits of injections and topical creams while minimizing their drawbacks. Full article
Show Figures

Graphical abstract

16 pages, 3597 KB  
Article
Towards a Customized Oral Drug Therapy for Pediatric Applications: Chewable Propranolol Gel Tablets Printed by an Automated Extrusion-Based Material Deposition Method
by Kristiine Roostar, Andres Meos, Ivo Laidmäe, Jaan Aruväli, Heikki Räikkönen, Leena Peltonen, Sari Airaksinen, Niklas Sandler Topelius, Jyrki Heinämäki and Urve Paaver
Pharmaceutics 2025, 17(7), 881; https://doi.org/10.3390/pharmaceutics17070881 - 4 Jul 2025
Viewed by 523
Abstract
Background: Automated semi-solid extrusion (SSE) material deposition is a promising new technology for preparing personalized medicines for different patient groups and veterinary applications. The technology enables the preparation of custom-made oral elastic gel tablets of active pharmaceutical ingredient (API) by using a semi-solid [...] Read more.
Background: Automated semi-solid extrusion (SSE) material deposition is a promising new technology for preparing personalized medicines for different patient groups and veterinary applications. The technology enables the preparation of custom-made oral elastic gel tablets of active pharmaceutical ingredient (API) by using a semi-solid polymeric printing ink. Methods: An automated SSE material deposition method was used for generating chewable gel tablets loaded with propranolol hydrochloride (-HCl) at three different API content levels (3.0 mg, 4.0 mg, 5.0 mg). The physical appearance, surface morphology, dimensions, mass and mass variation, process-derived solid-state changes, mechanical properties, and in-vitro drug release of the gel tablets were studied. Results: The inclusion of API (1% w/w) in the semi-solid CuraBlendTM printing mixture decreased viscosity and increased fluidity, thus promoting the spreading of the mixture on the printed (material deposition) bed and the printing performance of the gel tablets. The printed gel tablets were elastic, soft, jelly-like, chewable preparations. The mechanical properties of the gel tablets were dependent on the printing ink composition (i.e., with or without propranolol HCl). The maximum load for the final deformation of the CuraBlend™-API (3.0 mg) gel tablets was very uniform, ranging from 73 N to 80 N. The in-vitro dissolution test showed that more than 85% of the drug load was released within 15–20 min, thus verifying the immediate-release behavior of these drug preparations. Conclusions: Automated SSE material deposition as a modified 3D printing method is a feasible technology for preparing customized oral chewable gel tablets of propranolol HCl. Full article
Show Figures

Figure 1

Review

Jump to: Research

22 pages, 2122 KB  
Review
Micro and Nano Drug Delivery Systems for the Treatment of Oral Mucositis: A Review
by Luciana Ângela Soares Maia, Tâmara Thaiane Almeida Siqueira, Carlos Alberto Arcelly Santos Bezerra, Jéssica Horana Pereira de Farias and Elquio Eleamen Oliveira
Pharmaceutics 2025, 17(8), 1025; https://doi.org/10.3390/pharmaceutics17081025 - 7 Aug 2025
Viewed by 574
Abstract
Oral mucositis (OM) is a severe inflammatory condition of the oral mucosa that is commonly associated with cancer therapies. Traditional treatments typically have limited efficacy and significant side effects, necessitating alternative approaches. Nanobased drug delivery systems (DDSs) present promising solutions, enhancing therapeutic outcomes [...] Read more.
Oral mucositis (OM) is a severe inflammatory condition of the oral mucosa that is commonly associated with cancer therapies. Traditional treatments typically have limited efficacy and significant side effects, necessitating alternative approaches. Nanobased drug delivery systems (DDSs) present promising solutions, enhancing therapeutic outcomes while minimizing side effects. This review aims to evaluate the use of nanobased DDSs to treat OM. To reach these aims, an extensive literature review was conducted using the following databases: BVS, PubMed, Scopus, and Web of Science. The search strategy included the keywords “microparticles,” “nanoparticles,” “drug delivery system,” “oral mucositis,” “therapy,” and “treatment,” combined with the Boolean operators “AND” and “OR.” After applying filters for language, relevance, full-text availability, exclusion of review articles, and removal of duplicates, a total of 32 articles were selected for analysis. Of the 32 studies included in this review, 25 employed polymeric micro- or nanosystems for the treatment of OM. Regarding the stage of investigation, 10 studies were conducted in vitro, 16 were conducted in vivo, and 6 corresponded to clinical trials. Compared with conventional drug delivery approaches, most of these studies reported improved therapeutic outcomes. These findings highlight the potential of nanosystems as innovative strategies for enhancing OM treatment. Nonetheless, challenges in large-scale manufacturing, including reproducibility and safety, and the limited number of clinical trials warrant careful consideration. Future research with larger clinical trials is essential to validate these findings and effectively guide clinical practice. Full article
Show Figures

Figure 1

Back to TopTop